• Explore /
  • Poster
  • / Phase 1/2a clinical trial of BI-1206, an anti-CD32b (FcγRIIB) antibody, in combination with pembrolizumab in subjects with advanced solid tumors previously treated with anti-PD-1/PD-L1.

Phase 1/2a clinical trial of BI-1206, an anti-CD32b (FcγRIIB) antibody, in combination with pembrolizumab in subjects with advanced solid tumors previously treated with anti-PD-1/PD-L1.

Abstract Video & Slides Poster

Authors

Ana Carneiro

Ana Carneiro

Department of Hematology, Oncology and Radiation Physics, Skane University Hospital Comprehensive Cancer Center, Lund, Sweden

Ana Carneiro , Jeffrey Yachnin , Raid Aljumaily , Edvard Abel , Gerald Steven Falchook , Yan Ji , Marie Borggren , Linda Mårtensson , Susanne Gertsson , Ingrid Karlsson , Ingrid Teige , Johan Erik Wallin , Michael Jon Chisamore , Björn Frendeus , Andres McAllister , Ramin Tehranchi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

New Targets and New Technologies (IO)

Clinical Trial Registration Number

NCT04219254

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 2593)

DOI

10.1200/JCO.2024.42.16_suppl.2593

Abstract #

2593

Poster Bd #

72

Abstract Disclosures

Similar Posters

First Author: Neelima Vidula

First Author: Dung T. Le

First Author: XinCheng He

First Author: Montaser F. Shaheen